{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:01:56Z","timestamp":1792008116470,"version":"4.4.0"},"reference-count":123,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T00:00:00Z","timestamp":1478736000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":["kidney-international.theisn.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.kint.2016.10.004","type":"journal-article","created":{"date-parts":[[2016,12,18]],"date-time":"2016-12-18T12:19:05Z","timestamp":1482063545000},"page":"284-293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":156,"title":["Screening, diagnosis, and management of patients with Fabry disease: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference"],"prefix":"10.1016","volume":"91","author":[{"given":"Raphael","family":"Schiffmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derralynn A.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor E.","family":"Linthorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Svarstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Warnock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"Bichet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik Ils\u00f8","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Correa-Rotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry M.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Feriozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes B.","family":"Fogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique P.","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla E.M.","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Hopkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilkka","family":"Kantola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B.","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Kr\u00f6ner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ale\u0161","family":"Linhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich","family":"Matern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul B.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Mignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Najafian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiei","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg T.","family":"Obrador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Paulo","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Politei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Ramaswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Ries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Terryn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"T\u00f8ndel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roser","family":"Torra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bojan","family":"Vujkovac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Waldek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2016.10.004_bib1","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2016.10.004_bib2","series-title":"The Online Metabolic and Molecular Bases of inherited disease","article-title":"Alpha-galactosidase A deficiency: Fabry disease","author":"Desnick","year":"2014"},{"key":"10.1016\/j.kint.2016.10.004_bib3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10545-014-9677-8","article-title":"Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages","volume":"37","author":"Rombach","year":"2014","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.kint.2016.10.004_bib4","doi-asserted-by":"crossref","first-page":"780","DOI":"10.2119\/molmed.2012.00002","article-title":"Fabry disease: incidence of the common later-onset\u00a0alpha-galactosidase A IVS4+919G-->A mutation in\u00a0Taiwanese newborns\u2013superiority of DNA-based to enzyme-based newborn screening for common mutations","volume":"18","author":"Chien","year":"2012","journal-title":"Mol Med"},{"key":"10.1016\/j.kint.2016.10.004_bib5","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jacc.2007.06.062","article-title":"Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy","volume":"50","author":"Monserrat","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kint.2016.10.004_bib6","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ymgme.2014.11.004","article-title":"The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies","volume":"114","author":"Ferreira","year":"2015","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.kint.2016.10.004_bib7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2215\/CJN.02490607","article-title":"Screening for Fabry disease in patients with chronic kidney disease: limitations of plasma alpha-galactosidase assay as a screening test","volume":"3","author":"Andrade","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.10.004_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2009.01.003","article-title":"Fabry disease","volume":"122","author":"Schiffmann","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.kint.2016.10.004_bib9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/01.md.0000178976.62537.6b","article-title":"The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women","volume":"84","author":"Gupta","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.kint.2016.10.004_bib10","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/gim.2016.55","article-title":"Is it Fabry disease?","volume":"18","author":"Schiffmann","year":"2016","journal-title":"Genet Med"},{"key":"10.1016\/j.kint.2016.10.004_bib11","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.cca.2015.10.027","article-title":"Pitfalls in the detection of gross gene rearrangements using MLPA in Fabry disease","volume":"452","author":"Ferri","year":"2016","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.kint.2016.10.004_bib12","doi-asserted-by":"crossref","first-page":"e000394","DOI":"10.1161\/JAHA.113.000394","article-title":"Risk of death in heart disease is associated with elevated urinary globotriaosylceramide","volume":"3","author":"Schiffmann","year":"2014","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.kint.2016.10.004_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.kint.2016.10.004_bib14","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2016.10.004_bib15","series-title":"Fabry Disease: Perspectives from 5 Years of FOS","article-title":"Epidemiology of lysosomal storage diseases: an overview","author":"Fuller","year":"2006"},{"key":"10.1016\/j.kint.2016.10.004_bib16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.ejhg.5201044","article-title":"Prevalence of lysosomal storage diseases in Portugal","volume":"12","author":"Pinto","year":"2004","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.kint.2016.10.004_bib17","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1161\/STROKEAHA.112.663708","article-title":"Acute cerebrovascular disease in the young: the Stroke in Young Fabry Patients study","volume":"44","author":"Rolfs","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.kint.2016.10.004_bib18","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1016\/j.ijcard.2012.06.069","article-title":"Prevalence of\u00a0Fabry disease in a predominantly hypertensive population with\u00a0left ventricular hypertrophy","volume":"167","author":"Terryn","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.kint.2016.10.004_bib19","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1136\/heartjnl-2011-300364","article-title":"Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey","volume":"97","author":"Elliott","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.kint.2016.10.004_bib20","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10545-013-9659-2","article-title":"Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS)","volume":"37","author":"Palecek","year":"2014","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.kint.2016.10.004_bib21","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1097\/01.ASN.0000124671.61963.1E","article-title":"Results of a nationwide screening for Anderson-Fabry disease among dialysis patients","volume":"15","author":"Kotanko","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.10.004_bib22","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3109\/0886022X.2012.669300","article-title":"Identification of a novel mutation and prevalence study for fabry disease in Japanese dialysis patients","volume":"34","author":"Nishino","year":"2012","journal-title":"Ren Fail"},{"key":"10.1016\/j.kint.2016.10.004_bib23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.gene.2013.05.050","article-title":"Screening for Fabry disease in patients undergoing dialysis for chronic renal failure in Turkey: identification of new case with novel mutation","volume":"527","author":"Okur","year":"2013","journal-title":"Gene"},{"key":"10.1016\/j.kint.2016.10.004_bib24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1096-7192(03)00136-7","article-title":"Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma","volume":"80","author":"Froissart","year":"2003","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.kint.2016.10.004_bib25","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.10.005","article-title":"Prevalence of Fabry disease in young patients with cryptogenic ischemic stroke","volume":"22","author":"Dubuc","year":"2013","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.kint.2016.10.004_bib26","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1186\/s13104-015-1696-5","article-title":"Late diagnosis of Fabry disease caused by a de novo mutation in a patient with end stage renal disease","volume":"8","author":"Pisani","year":"2015","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.kint.2016.10.004_bib27","series-title":"Fabry Disease: Perspectives from 5 Years of FOS","article-title":"A\u00a0multidisciplinary approach to the care of patients with Fabry disease","author":"Hughes","year":"2006"},{"key":"10.1016\/j.kint.2016.10.004_bib28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.kint.2016.10.004_bib29","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet Med"},{"key":"10.1016\/j.kint.2016.10.004_bib30","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/ncpneph0806","article-title":"Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults","volume":"4","author":"Ortiz","year":"2008","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.kint.2016.10.004_bib31","doi-asserted-by":"crossref","first-page":"e0124987","DOI":"10.1371\/journal.pone.0124987","article-title":"Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial","volume":"10","author":"Wijburg","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2016.10.004_bib32","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"Tondel","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.10.004_bib33","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2016.10.004_bib34","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/jmedgenet-2015-103486","article-title":"Time to treatment benefit for adult patients with Fabry disease receiving agalsidase beta: data from the Fabry Registry","volume":"53","author":"Ortiz","year":"2016","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.kint.2016.10.004_bib35","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","article-title":"Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications","volume":"274","author":"Weidemann","year":"2013","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.kint.2016.10.004_bib36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ymgmr.2015.02.002","article-title":"Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis","volume":"3","author":"Beck","year":"2015","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.kint.2016.10.004_bib37","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1053\/j.ajkd.2006.12.005","article-title":"KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease","volume":"49","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2016.10.004_bib38","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.10.004_bib39","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.kint.2016.10.004_bib40","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1681\/ASN.2008080870","article-title":"Agalsidase alfa and kidney dysfunction in Fabry disease","volume":"20","author":"West","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.10.004_bib41","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ndt\/gfp554","article-title":"End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry","volume":"25","author":"Ortiz","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2016.10.004_bib42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000369309","article-title":"Foot process effacement is an early marker of nephropathy in young classic fabry patients without albuminuria","volume":"129","author":"Tondel","year":"2015","journal-title":"Nephron Physiol"},{"key":"10.1016\/j.kint.2016.10.004_bib43","first-page":"791","article-title":"Podocyturia is significantly elevated in untreated vs treated Fabry adult patients","volume":"29","author":"Trimarchi","year":"2016","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.kint.2016.10.004_bib44","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.kint.2016.10.004_bib45","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2016.10.004_bib46","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1750-1172-8-47","article-title":"Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain","volume":"8","author":"Rombach","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.kint.2016.10.004_bib47","first-page":"CD006663","article-title":"Enzyme replacement therapy for Anderson-Fabry disease","volume":"7","author":"El Dib","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.kint.2016.10.004_bib48","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","article-title":"Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry","volume":"40","author":"Sims","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.kint.2016.10.004_bib49","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s10545-014-9717-4","article-title":"Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study","volume":"37","author":"Anderson","year":"2014","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.kint.2016.10.004_bib50","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1136\/jnnp.2008.143693","article-title":"Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study","volume":"79","author":"Buechner","year":"2008","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.kint.2016.10.004_bib51","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1159\/000369293","article-title":"Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease","volume":"38","author":"Fellgiebel","year":"2014","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.kint.2016.10.004_bib52","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A\u00a0phase 1\/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.kint.2016.10.004_bib53","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2016.10.004_bib54","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1477-7525-10-116","article-title":"Measuring patient experiences in Fabry disease: validation of the Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ)","volume":"10","author":"Ramaswami","year":"2012","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.kint.2016.10.004_bib55","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1542\/peds.2005-2895","article-title":"Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease","volume":"118","author":"Ries","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.kint.2016.10.004_bib56","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpeds.2007.09.007","article-title":"Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease","volume":"152","author":"Wraith","year":"2008","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.kint.2016.10.004_bib57","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ymgme.2005.04.009","article-title":"Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy","volume":"85","author":"Banikazemi","year":"2005","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.kint.2016.10.004_bib58","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.cgh.2007.08.012","article-title":"Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy","volume":"5","author":"Hoffmann","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.kint.2016.10.004_bib59","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1023\/B:BOLI.0000009948.86528.72","article-title":"Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy","volume":"26","author":"Hajioff","year":"2003","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.kint.2016.10.004_bib60","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1365-2362.2006.01701.x","article-title":"Agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome Survey","volume":"36","author":"Hajioff","year":"2006","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.kint.2016.10.004_bib61","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10545-014-9783-7","article-title":"Hearing loss in adult patients with Fabry disease treated with enzyme replacement therapy","volume":"38","author":"Suntjens","year":"2015","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.kint.2016.10.004_bib62","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13023-015-0296-8","article-title":"Quality of life in patients with Fabry disease: a systematic review of the literature","volume":"10","author":"Arends","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.kint.2016.10.004_bib63","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s10545-015-9845-5","article-title":"A\u00a0prospective 10-year study of individualized, intensified enzyme replacement therapy in advanced Fabry disease","volume":"38","author":"Schiffmann","year":"2015","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.kint.2016.10.004_bib64","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ymgme.2014.01.014","article-title":"Outcomes of patients treated through the Canadian Fabry disease initiative","volume":"111","author":"Sirrs","year":"2014","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.kint.2016.10.004_bib65","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbadis.2010.09.007","article-title":"Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy","volume":"1812","author":"van Breemen","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.kint.2016.10.004_bib66","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","article-title":"Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3","volume":"94","author":"Vedder","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.kint.2016.10.004_bib67","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/gim.2013.56","article-title":"Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa","volume":"15","author":"Schiffmann","year":"2013","journal-title":"Genet Med"},{"key":"10.1016\/j.kint.2016.10.004_bib68","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/B978-0-444-62702-5.00017-2","article-title":"Fabry disease","volume":"132","author":"Schiffmann","year":"2015","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.kint.2016.10.004_bib69","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry's disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2016.10.004_bib70","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/GIM.0b013e3181981d82","article-title":"Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease","volume":"11","author":"Lubanda","year":"2009","journal-title":"Genet Med"},{"key":"10.1016\/j.kint.2016.10.004_bib71","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1681\/ASN.2014121226","article-title":"Serum-mediated inhibition of enzyme replacement therapy in Fabry disease","volume":"27","author":"Lenders","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.10.004_bib72","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmg.2008.065904","article-title":"Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey","volume":"46","author":"Mehta","year":"2009","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.kint.2016.10.004_bib73","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry","volume":"11","author":"Waldek","year":"2009","journal-title":"Genet Med"},{"key":"10.1016\/j.kint.2016.10.004_bib74","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey","volume":"28","author":"Linhart","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kint.2016.10.004_bib75","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.amjcard.2005.05.033","article-title":"Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease","volume":"96","author":"Shah","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.kint.2016.10.004_bib76","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1590\/S1807-59322010000700012","article-title":"Anti-hypertensive drugs have different effects on ventricular hypertrophy regression","volume":"65","author":"Ferreira Filho","year":"2010","journal-title":"Clinics (Sao\u00a0Paulo)"},{"key":"10.1016\/j.kint.2016.10.004_bib77","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0002-8703(97)70095-4","article-title":"Long-term effects of angiotensin-converting enzyme inhibitors and calcium antagonists on the right and left ventricles in essential hypertension","volume":"134","author":"Lombardo","year":"1997","journal-title":"Am Heart J"},{"key":"10.1016\/j.kint.2016.10.004_bib78","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease","volume":"43","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2016.10.004_bib79","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kint.2016.10.004_bib80","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.02.019","article-title":"Characteristics of cerebral microbleeds in patients with Fabry disease","volume":"25","author":"Kono","year":"2016","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.kint.2016.10.004_bib81","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/STROKEAHA.114.006283","article-title":"Cerebrovascular involvement in Fabry disease: current status of knowledge","volume":"46","author":"Kolodny","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.kint.2016.10.004_bib82","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1146\/annurev-med-090910-085119","article-title":"The Fabry cardiomyopathy: models for the cardiologist","volume":"62","author":"Weidemann","year":"2011","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.kint.2016.10.004_bib83","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jcmg.2011.01.020","article-title":"Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment","volume":"4","author":"Niemann","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.kint.2016.10.004_bib84","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/clc.22047","article-title":"Arrhythmias in Fabry cardiomyopathy","volume":"35","author":"Acharya","year":"2012","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.kint.2016.10.004_bib85","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1161\/CIRCULATIONAHA.106.178233","volume":"114","author":"Zipes","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2016.10.004_bib86","first-page":"2","article-title":"Fabry disease, respiratory symptoms, and airway limitation - a systematic review","author":"Svensson","year":"2015","journal-title":"Eur Clin Respir J"},{"key":"10.1016\/j.kint.2016.10.004_bib87","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.kint.2016.10.004_bib88","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/gim.2014.120","article-title":"Fabry disease in infancy and early childhood: a systematic literature review","volume":"17","author":"Laney","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.kint.2016.10.004_bib89","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2377-11-61","article-title":"Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel","volume":"11","author":"Burlina","year":"2011","journal-title":"BMC Neurol"},{"key":"10.1016\/j.kint.2016.10.004_bib90","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1468-1331.2010.02999.x","article-title":"EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision","volume":"17","author":"Attal","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.kint.2016.10.004_bib91","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/cns.12542","article-title":"Pain in Fabry disease: practical recommendations for diagnosis and treatment","volume":"22","author":"Politei","year":"2016","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.kint.2016.10.004_bib92","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cge.12673","article-title":"Gastrointestinal involvement in Fabry disease. So important, yet often neglected","volume":"89","author":"Politei","year":"2016","journal-title":"Clinical Genetics"},{"key":"10.1016\/j.kint.2016.10.004_bib93","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1126\/science.172.3979.174","article-title":"Fabry's disease: antenatal detection","volume":"172","author":"Brady","year":"1971","journal-title":"Science"},{"key":"10.1016\/j.kint.2016.10.004_bib94","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10545-006-0196-0","article-title":"Manifestations of Fabry disease in placental tissue","volume":"29","author":"Vedder","year":"2006","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.kint.2016.10.004_bib95","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ki.2010.484","article-title":"Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease","volume":"79","author":"Najafian","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.10.004_bib96","first-page":"257628","article-title":"Copious podocyturia without proteinuria and with normal renal function in a young adult with Fabry disease","author":"Trimarchi","year":"2015","journal-title":"Case Rep Nephrol"},{"key":"10.1016\/j.kint.2016.10.004_bib97","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1093\/ndt\/gfq108","article-title":"The value of estimated GFR in comparison to measured GFR for the assessment of renal function in adult patients with Fabry disease","volume":"25","author":"Rombach","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2016.10.004_bib98","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/ndt\/gfp658","article-title":"Monitoring renal function in children with Fabry disease: comparisons of measured and creatinine-based estimated glomerular filtration rate","volume":"25","author":"Tondel","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2016.10.004_bib99","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1681\/ASN.2006101081","article-title":"Progression risk, urinary protein excretion, and treatment effects of Angiotensin-converting enzyme inhibitors in nondiabetic kidney disease","volume":"18","author":"Kent","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.10.004_bib100","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1136\/bmj.319.7201.24","article-title":"Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria","volume":"319","author":"Mathiesen","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.kint.2016.10.004_bib101","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa0808400","article-title":"Renal and retinal effects of enalapril and losartan in type 1 diabetes","volume":"361","author":"Mauer","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2016.10.004_bib102","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2016.10.004_bib103","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.2337\/dc11-0324","article-title":"Initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial","volume":"34","author":"Hellemons","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2016.10.004_bib104","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000357593","article-title":"Perspective on combination RAS blocking therapy: off-TARGET, dis-CORD, MAP-to-nowhere, low ALTITUDE, and NEPHRON-D","volume":"39","author":"Luft","year":"2014","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2016.10.004_bib105","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2016.10.004_bib106","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2215\/CJN.04340510","article-title":"Prognostic indicators of renal disease progression in adults with fabry disease: natural history data from the fabry registry","volume":"5","author":"Wanner","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.10.004_bib107","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","article-title":"Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation","volume":"27","author":"Warnock","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2016.10.004_bib108","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/ndt\/gfs526","article-title":"Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice","volume":"28","author":"Terryn","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2016.10.004_bib109","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/jmedgenet-2015-103471","article-title":"Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy","volume":"52","author":"Warnock","year":"2015","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.kint.2016.10.004_bib110","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ymgme.2014.08.007","article-title":"Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosis","volume":"114","author":"van der Tol","year":"2015","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.kint.2016.10.004_bib111","doi-asserted-by":"crossref","unstructured":"Skrunes R, Svarstad E, Kampevold Larsen K, et\u00a0al. Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients [e-pub ahead of print]. Nephrol Dial Transplant. http:\/\/dx.doi.org\/10.1093\/ndt\/gfw094.","DOI":"10.1093\/ndt\/gfw094"},{"key":"10.1016\/j.kint.2016.10.004_bib112","first-page":"854521","article-title":"Amiloride as an alternate adjuvant antiproteinuric agent in Fabry disease: the potential roles of plasmin and uPAR","volume":"2014","author":"Trimarchi","year":"2014","journal-title":"Case Rep Nephrol"},{"key":"10.1016\/j.kint.2016.10.004_bib113","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/ndt\/gfu273","article-title":"Antiproteinuric effect of add-on paricalcitol in Fabry disease patients: a prospective observational study","volume":"30","author":"Pisani","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2016.10.004_bib114","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ejim.2013.05.003","article-title":"Pulmonary involvement in Fabry disease: overview and perspectives","volume":"24","author":"Franzen","year":"2013","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.kint.2016.10.004_bib115","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1212\/WNL.39.4.598","article-title":"Carbamazepine in Fabry's disease: effective analgesia with dose-dependent exacerbation of autonomic dysfunction","volume":"39","author":"Filling-Katz","year":"1989","journal-title":"Neurology"},{"key":"10.1016\/j.kint.2016.10.004_bib116","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12883-016-0549-8","article-title":"Pain management strategies for neuropathic pain in Fabry disease - a systematic review","volume":"16","author":"Schuller","year":"2016","journal-title":"BMC Neurol"},{"key":"10.1016\/j.kint.2016.10.004_bib117","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1025127723729","article-title":"Use of gabapentin to reduce chronic neuropathic pain in Fabry disease","volume":"26","author":"Ries","year":"2003","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.kint.2016.10.004_bib118","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1212\/WNL.23.8.871","article-title":"Relief of pain of Fabry's disease by diphenylhydantoin","volume":"23","author":"Lockman","year":"1973","journal-title":"Neurology"},{"key":"10.1016\/j.kint.2016.10.004_bib119","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/qjmed\/hcq117","article-title":"Fabry disease: a review of current management strategies","volume":"103","author":"Mehta","year":"2010","journal-title":"QJM"},{"key":"10.1016\/j.kint.2016.10.004_bib120","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00108-012-3204-5","article-title":"Pain therapy for Fabry\u2019s disease","volume":"54","author":"Sommer","year":"2012","journal-title":"Der Internist"},{"key":"10.1016\/j.kint.2016.10.004_bib121","doi-asserted-by":"crossref","first-page":"166","DOI":"10.33588\/rn.4903.2009100","article-title":"[Intravenous lidocaine as treatment for the painful episodes in Fabry's disease]","volume":"49","author":"Politei","year":"2009","journal-title":"Rev Neurol"},{"key":"10.1016\/j.kint.2016.10.004_bib122","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.amjmed.2009.04.007","article-title":"Treatment of neuropathic pain: an overview of recent guidelines","volume":"122","author":"O'Connor","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.kint.2016.10.004_bib123","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","article-title":"Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry","volume":"30","author":"Eng","year":"2007","journal-title":"J\u00a0Inherit Metab Dis"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253816306032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253816306032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T14:29:27Z","timestamp":1749824967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253816306032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":123,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0085253816306032"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2016.10.004","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Screening, diagnosis, and management of patients with Fabry disease: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2016.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016, International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}